🔴 The European Commission fines Teva €462.6 million over misuse of the patent system and disparagement to delay rival multiple sclerosis medicine 👇 ⛔ The Commission found that Teva abused its dominant position to delay competition to its blockbuster medicine for treating multiple sclerosis, Copaxone. This was done by artificially extending Copaxone's patent protection and systematically spreading misleading information about a competing product to hinder its market entry and uptake. 🔍 Our investigation found that Teva abused its dominant position in the markets for glatiramer acetate in Belgium, Czechia, Germany, Italy, the Netherlands, Poland and Spain.❌ Today's decision concludes that Teva's abuses were complementary and together amounted to a single and continuous infringement of EU law.💉 This is the first time the Commission has imposed a fine in relation to these two types of practices.